"We are now witnessing activism on steroids," and "no company or industry is immune."
Barrett Golden, partner at Joele Frank, speaking at a session (Managing Your Response to Activist Shareholders) at the BIO 2015 International Convention

"The currently available FDA-approved AD treatments are routinely used in clinical practice, but many experts consider that their relatively low level of effectiveness does not justify their costs. Given that up to one-third of people may develop dementia in old age, finding more effective treatments for AD and other dementias will benefit huge numbers of people."
Joseph Kwan, a clinical associate professor of gerontology with the Department of Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong

"For several years there has arguably been a gap in the availability of sufficient capital to either attract internationally recognized senior managers to build new biotechs on university IP, or to get early proof-of-concept experiments completed that would have facilitated international venture capitalists to back [Oxford University] spinout companies."
Jon Rees, CEO, OBN Ltd. (formerly Oxfordshire Biosciences Network), on Oxford University's new technology commercialization body, Oxford Science Innovation plc, closing its first fund at $505.7 million